|
|
Profile
|
Delegates :
Dr. Kiyoshi Nokihara |
|
Incorporated :
March 29 , 2002 |
Paid in Capital :
22 Million yen |
Employees :
8 人 |
Address :
Nakatsukasa-cho, 486-46, Kamigyo-ku, Kyoto, 602-8158, Japan KYOTO
〒602-8158
|
TEL/FAX :
+81-75-813-2101 / +81-75-801-0280 |
URL：
httsp://www.hipep.com |
Attachment :
 HiPep_O-001E_2022.pdf [ 1.7MiB ] |
Mission/Background :
Based on academic research in an interdisciplinary field as well as business experiences, HiPep Laboratories was founded in 2002 focusing on applications of molecular recognition, diagnostics and theranostics. The concept is that biomolecules such as proteins can be mimicked by peptides. Recently development of microarray systems, PepTenChip (R), for biodetection has been completed. In addition to proteins, DNA recognition by peptides consisting of pyrrole and imidazole (PIPA) has been also commercialized. |
|
Technology & Business
|
The core technology, designated HiPep(R) Technology, is highly efficient construction and characterization of structured peptides and their conjugates. HiPep has developed unique laboratory devices and reagents for in-house use and delivered as commercial products in research supporting. Products/licensing/collaboration as follows:
[1] Novel biodetection systems, PepTenChip(R);
[2] Libraries of peptides and cyclotides immobilized on gel-type beads based on the “one peptide on one bead" concept (diversity: ca 200 millions); bio-conjugates (drug delivery technology, peptide-vehicles). Novel focusing drug-likeness libraries. Deconvolution service available.
[3] Angiogenic peptides for regenerative medicine (US, EU & JP-PAT) which showed no permeation;
[4] Non-proteinogenic amino acid, Mimosine, and derivatives.
[5] Reagents, devices with consumers and unique HPLC-columns originally developed for in-house use.
[6] PIPA-derivatives for gene-control, DNA visualization and API.
[7] Contract research.
|
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
PepTenChip(R), novel biodetection systems
|
Preclinical
|
Peptides micro array, non-disposable amorphous carbon plates, detector
|
Clinical tests followed by approval (medical device category I)
|
Angiogenic peptides and their conjugates
|
Preclinical
|
Strong angiogenesis and SAR, endogenous enzyme resistant
|
Licensing and collaboration for clinical tests
|
Pyrrole Imidazole Polyamide, PIPA
|
Preclinical
|
API, Prove for DNA visualization
|
Telomere visualization; GMP-production is planned.
|
Devices/consumers
|
Launched
|
Efficient library construction, technology know-how transfer
|
Bio-detection, drug development, cancer-DDS, cosmeceuticals
|
Mimosine, non-proteinogenic amino acid, and mimosyl-peptides
|
Discovery
|
Mimosyl-peptides for API or cosmeceutical ingredients
|
Material supply/collaboration
|
|
Highlights
|
1. Novel biodetection system, PepTenChip(R), arrayed with labeled structured peptides for bio-detection (patented: EU, US & JP) is completed together with chip-substrate made from amorphous carbon. The maintenance free detector, PepTenCam, is also launched.
2. Production system for PIPA (peptides consisting of pyrrole and imidazole as major building blocks), recognizing DNA with sequence specific manner, has been performed. PIPA can be applied to novel drugs and molecular probes for DNA.
|
|
Hot news
|
PepTenChip(R) provides objective results. Preclinical experiments in neuronal diseases and pre-cancer detection are underway. The system allows noninvasive diagnostics, real-time on-site POC, thus it can be applied to remote diagnostics and home medical-care.
|
|
Alliance strategy
|
Technology transfer concerning to biomolecular recognition and product sales: the novel bio-detection system; various peptide-based libraries for drug discovery and optimization; bio-conjugates (peptide-vehicle for DDS); long lasting angiogenic agents for regenerative medicine; PIPA for DNA-targeting probes or API; non-proteinogenic amino acid, mimosine containing derivatives as novel ingredients of drugs or cosmeceuticals. Consultation and contract research.
|
|
|